Bevacizumab and irinotecan in recurrent malignant glioma, a single institution experience

Data publikacji: 03 mar 2015

Zakres stron: 80 - 85

Otrzymano: 09 wrz 2013

Przyjęty: 08 lis 2013

DOI: https://doi.org/10.2478/raon-2014-0021

Słowa kluczowe

recurrent malignant glioma, bevacizumab, irinotecan, systemic therapy

© by Janja Ocvirk

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.